Literature DB >> 7780986

Expression of peripheral-type benzodiazepine receptor and diazepam binding inhibitor in human astrocytomas: relationship to cell proliferation.

H Miettinen1, J Kononen, H Haapasalo, P Helén, P Sallinen, T Harjuntausta, H Helin, H Alho.   

Abstract

The expression of peripheral-type benzodiazepine receptor (PBR) and diazepam binding inhibitor (DBI) were studied in human astrocytic tumors using immunocytochemistry and in situ hybridization. Both PBR and DBI were prominently expressed in neoplastic cells, whereas in normal brain their amount was low or undetectable. Immunocytochemical double staining demonstrated that PBR and DBI were present in the same cells, suggesting that DBI may act in an autocrine manner in these cells. Analysis of 86 cases showed that PBR expression was statistically significantly associated with tumor malignancy grade (P = 0.004) and the proliferative index as determined by immunocytochemistry with the MIB-1 antibody (P = 0.004). Patients having tumors with high levels of PBR-immunoreactive cells had a shorter life expectancy than patients whose tumors showed lower PBR contents (P = 0.024). In conclusion, these results show that PBR expression is higher in neoplastic cells than in normal brain tissue. They also suggest that PBR immunocytochemistry might be useful in evaluating malignancy in brain tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7780986

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

Review 1.  The peripheral benzodiazepine receptors: a review.

Authors:  A Beurdeley-Thomas; L Miccoli; S Oudard; B Dutrillaux; M F Poupon
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

Review 2.  Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states.

Authors:  Amani Batarseh; Vassilios Papadopoulos
Journal:  Mol Cell Endocrinol       Date:  2010-06-30       Impact factor: 4.102

3.  Expression of fatty acyl-CoA binding proteins in colon cells: response to butyrate and transformation.

Authors:  R E Gossett; F Schroeder; J M Gunn; A B Kier
Journal:  Lipids       Date:  1997-06       Impact factor: 1.880

4.  The mitochondrial translocator protein, TSPO, inhibits HIV-1 envelope glycoprotein biosynthesis via the endoplasmic reticulum-associated protein degradation pathway.

Authors:  Tao Zhou; Ying Dang; Yong-Hui Zheng
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

5.  11C-PBR28 PET detects translocator protein in a patient with astrocytoma and Alzheimer disease.

Authors:  William C Kreisl; Robin Lawrence; Emily Page; Andrew F Teich; Deepa S Subramaniam; Robert B Innis; R Scott Turner
Journal:  Neurology       Date:  2017-02-08       Impact factor: 9.910

6.  Preclinical imaging evaluation of novel TSPO-PET ligand 2-(5,7-Diethyl-2-(4-(2-[(18)F]fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide ([ (18)F]VUIIS1008) in glioma.

Authors:  Dewei Tang; Michael L Nickels; M Noor Tantawy; Jason R Buck; H Charles Manning
Journal:  Mol Imaging Biol       Date:  2014-12       Impact factor: 3.488

Review 7.  Pharmacological regulation of gene expression.

Authors:  Italo Mocchetti
Journal:  Pharmacol Res       Date:  2011-06-16       Impact factor: 7.658

8.  TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study.

Authors:  M Unterrainer; D F Fleischmann; F Vettermann; V Ruf; L Kaiser; D Nelwan; S Lindner; M Brendel; V Wenter; S Stöcklein; J Herms; V M Milenkovic; R Rupprecht; J C Tonn; C Belka; P Bartenstein; M Niyazi; N L Albert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-05       Impact factor: 9.236

9.  Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain.

Authors:  M Cosenza-Nashat; M-L Zhao; H-S Suh; J Morgan; R Natividad; S Morgello; S C Lee
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12-11       Impact factor: 8.090

10.  Translocator protein blockade reduces prostate tumor growth.

Authors:  Arlee Fafalios; Ardavan Akhavan; Anil V Parwani; Robert R Bies; Kevin J McHugh; Beth R Pflug
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.